Saturday 17 October 2026
Export LMRI’s income statement to Excel — free account
Lumexa Imaging Holdings, Inc.
LMRI Healthcare Medical Devices
Lumexa Imaging Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.0 billion, up 7.82% from fiscal 2024. In the quarter to June 2026, revenue grew 7.82%, EPS grew 127.1% and free cash flow grew 257.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
10.78
0.00
0.00%
Follow LMRI
| Older periods | Jun '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+3 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.00 | 0.00 | 0.47 | 0.60 | |
P/FCF ratio |
128.20 | 0.00 | 0.00 | 72.51 | |
P/Operating CF |
621.15 | 76.91 | 281.53 | 33.01 | |
P/B ratio |
7.97 | 2.24 | 1.38 | 1.76 | |
Price to Tangible BV |
7.97 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.00 | 0.00 | 0.93 | 1.05 | |
EV/EBITDA |
0.00 | 0.00 | 1.44 | 1.66 | |
EV/Operating CF |
37.36 | 46.17 | 202.43 | 34.41 | |
EV/FCF |
246.79 | (293.46) | (71.81) | 126.46 | |
Quick Ratio |
— | 1.17 | 1.30 | 1.36 | |
Current Ratio |
— | 1.27 | 1.41 | 1.44 | |
Net Debt/EBITDA |
0.00 | 0.79 | 23.93 | 20.96 | |
Debt/Assets |
0.00% | 49.04% | 49.28% | 48.39% | |
Debt/Equity |
0.00 | 1.48 | 1.45 | 1.42 | |
Asset Turnover |
— | 0.00 | 1.03 | 1.98 | |
Operating CF/Net income |
(0.29) | (0.36) | 1.71 | 11.95 | |
Capex/Depreciation |
(0.29) | (0.34) | (0.36) | (0.63) | |
Interest Coverage |
0.92 | — | 1.19 | 1.42 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
7.43% | 0.00% | 8.05% | 9.24% | |
Intangible Assets out of Total Assets |
0.00 | 0.48 | 0.48 | 0.47 | |
Share Based Compensation of Revenue |
3.32% | 0.00% | 4.86% | 4.82% | |
Graham Net Nets |
(1.04) | (0.72) | (1.14) | (0.87) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(9.94%) | (9.94%) | (9.94%) | (6.33%) | |
Free Cash Flow Yield |
0.78% | (0.55%) | (2.77%) | 1.38% | |
Revenue per Share |
3.62 | 14.41 | 2.63 | 2.75 | |
Operating CF per Share |
0.03 | 0.24 | 0.03 | 0.34 | |
Capex per Share |
(0.06) | (0.29) | (0.05) | (0.10) | |
Free Cash Flow per Share |
(0.03) | (0.05) | (0.02) | 0.24 | |
Cash per Share |
0.00 | 0.83 | 0.53 | 0.73 | |
Shareholders Equity per Share |
0.00 | 8.26 | 6.25 | 6.41 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 8.26 | 6.25 | 6.41 | |
Free Cash Flow |
(2.10) | (3.76) | (2.34) | 23.13 | |
Working Capital |
— | 48.07 | 63.96 | 78.06 | |
Capital Expenditures |
(4.17) | (20.83) | (5.27) | (9.67) | |
Net Current Asset Value |
0.00 | (951.17) | (941.84) | (937.29) | |
EV/EBIT |
0.00 | 0.00 | 1.50 | 1.73 | |
Capex to Sales |
0.02 | 0.02 | 0.02 | 0.04 | |
Price to Operating Income |
0.00 | 0.00 | 0.75 | 0.99 | |
| Other line items | |||||
Average Assets |
— | 882.28 | 1,716.96 | 904.39 |
Columns are period end dates